Article
Oncology
Kuo-Cheng Wu, I-Cheng Lee, Chen-Ta Chi, Hao-Jan Lei, Gar-Yang Chau, Yi-Chen Yeh, Chien-Wei Su, Teh-la Huo, Yee Chao, Han-Chieh Lin, Ming-Chih Hou, Yi-Hsiang Huang
Summary: This study compared the outcomes of HCV-related HCC patients after achieving SVR through IFN-based or DAA therapy following resection, finding that achieving SVR with either treatment results in a significant reduction in mortality and hepatic decompensation. This benefit was observed in both cirrhotic and non-cirrhotic patients, as well as in those with and without HCC recurrence. Therefore, DAA therapy should be considered for all HCC patients after curative surgical resection.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Roberto Cannella, Federica Vernuccio, Ciro Celsa, Giuseppe Cabibbo, Vincenza Calvaruso, Silvia Greco, Salvatore Battaglia, Kingshuk Roy Choudhury, An Tang, Massimo Midiri, Vito Di Marco, Calogero Camma, Giuseppe Brancatelli
Summary: The study found that DAA therapy does not increase the progression of indeterminate observations to malignant categories. The initial LI-RADS category is an independent predictor of observations upgrade.
LIVER INTERNATIONAL
(2021)
Review
Medicine, General & Internal
Pil Soo Sung, Eui-Cheol Shin
Summary: The use of DAAs in treating chronic HCV infection can lead to rapid changes in the phenotypes of NK and MAIT cells, potentially reducing their cytotoxicity against cancer cells. Additionally, DAAs treatment does not normalize the increased frequencies of regulatory T cells, which may contribute to local immunosuppression and hinder cancer cell clearance.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Eiichi Ogawa, Hideyuki Nomura, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Jun Hayashi
Summary: This study reveals that older patients aged 75-84 years remain at high risk for developing HCC even after the elimination of HCV and improvement of the FIB-4 index to <3.25.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Gastroenterology & Hepatology
Hironori Ochi, Atsushi Hiraoka, Masashi Hirooka, Yohei Koizumi, Michiko Amano, Nobuaki Azemoto, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Toshie Mashiba, Tomoyuki Yokota, Masanori Abe, Kojiro Michitaka, Yoichi Hiasa, Kouji Joko
Summary: DAAs treatment after HCC can prevent hepatic functional reserve deterioration and significantly improve both recurrence and survival rates. This study showed that in patients receiving DAAs treatment, the 48-month survival rate was 91.0% and the recurrence rate was 36.7%, both significantly better than in patients not receiving DAAs treatment.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Virology
Cassia Leal, Jorge Strogoff-de-Matos, Carmem Theodoro, Rosangela Teixeira, Renata Perez, Thais Guarana, Paulo de Tarso Pinto, Tatiana Guimaraes, Solange Artimos
Summary: This study investigated the incidence and risk factors for hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs). Among 1075 HCV patients, 4.7% developed HCC within a median follow-up period of 40 months. The main risk factors identified were non-characterized nodules, cirrhosis, high alpha-fetoprotein values, and non-sustained virological response (SVR). The findings suggest that although HCV cure reduces the risk of HCC, vigilance is still required, particularly for cirrhotic patients.
Review
Medicine, General & Internal
Leonardo Frazzoni, Usama Sikandar, Flavio Metelli, Sinan Sadalla, Giuseppe Mazzella, Franco Bazzoli, Lorenzo Fuccio, Francesco Azzaroli
Summary: Research shows that approximately 30% of patients with a history of HCC will experience HCC recurrence after receiving DAA treatment, with the risk of recurrence higher soon after treatment ends. Studies from Europe, the United States, Egypt, and Asia show variations in recurrence rates, but overall, DAA treatment seems to lower the risk of HCC recurrence compared to IFN and no intervention.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Pierre Nahon, Erwan Vo Quang, Nathalie Ganne-Carrie
Summary: The incidence of hepatocellular carcinoma has decreased in patients infected with HCV and HBV thanks to antiviral drugs, but those with advanced fibrosis or cirrhosis still face risk. Predictors of cancer in virus-free patients include comorbidities, liver inflammation, and non-invasive test results, allowing for stratification and surveillance. International guidelines recommend lifelong monitoring with ultrasound, and further research into more effective surveillance tools is needed for personalized management.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Mohamed AbdAllah, Mohamed Alboraie, Wael Abdel-Razek, Mohamed Hassany, Islam Ammar, Ehab Kamal, Mahmoud Alalfy, Ahmed Okasha, Wafaa El Akel, Elsaied Shaaban, Tamer Elbaz, Zeinab Hefny, Ahmed Gomaa, Mahmoud El-Bendary, Magdy El-Serafy, Gamal Esmat, Wahid Doss, Manal H. El-Sayed
Summary: The study showed that most pregnant women undergoing HCV treatment chose to stop between weeks 4-8, but those who completed the full course delivered healthy babies and achieved a good treatment response, with no major adverse events reported.
LIVER INTERNATIONAL
(2021)
Review
Gastroenterology & Hepatology
Ciro Celsa, Caterina Stornello, Paolo Giuffrida, Carmelo Marco Giacchetto, Mauro Grova, Gabriele Rancatore, Concetta Pitrone, Vito Di Marco, Calogero Camma, Giuseppe Cabibbo
Summary: DAAs have revolutionized the treatment of chronic HCV-related disease, showing positive effects in HCC patients and proving to be effective regardless of HCC status. Studies indicate that HCC status does not affect the likelihood of achieving SVR with DAAs, making them suitable for active HCC patients.
ANNALS OF HEPATOLOGY
(2022)
Article
Surgery
Michael K. Turgeon, Shimul A. Shah, Aaron M. Delman, Benjamin Tran, Vatche G. Agopian, Joel P. Wedd, Joseph F. Magliocca, Ahyoung Kim, Andrew Cameron, Ali Olyaei, Susan L. Orloff, Matthew P. Anderson, Chandrashekhar A. Kubal, Robert M. Cannon, Jayme E. Locke, Mary A. Simpson, Mohamed E. Akoad, Chelsey P. Wongjirad, Juliet Emamaullee, Amika Moro, Federico Aucejo, Cyrus A. Feizpour, Parsia A. Vagefi, Mindie H. Nguyen, Carlos O. Esquivel, Kiran Dhanireddy, Vijay Subramanian, Alejandro Chavarriaga, Marwan M. Kazimi, Maia S. Anderson, Christopher J. Sonnenday, Steven C. Kim, David P. Foley, Marwan Abdouljoud, Reena J. Salgia, Dimitrios Moris, Debra L. Sudan, Swaytha R. Ganesh, Abhinav Humar, Majella Doyle, William C. Chapman, Shishir K. Maithel
Summary: The optimal timing of DAA therapy in patients with HCV-associated HCC undergoing LT appears to be 0 to 3 months post-LT, leading to increased rates of SVR and improved RFS. Delayed administration after transplant should be avoided. Additional prospective randomized controlled trials are needed to validate these findings.
Article
Health Care Sciences & Services
Xinyi Jiang, Hyun Jin Song, Ching-Yuan Chang, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic, Haesuk Park
Summary: This study examined the effects of all-oral direct-acting antivirals (DAAs) on hepatocellular carcinoma (HCC) and liver-related and all-cause mortality among Medicaid beneficiaries with hepatitis C virus (HCV). The results showed that DAA treatment was associated with a lower risk of HCC in patients with compensated cirrhosis (CC), but not in patients without cirrhosis or with decompensated cirrhosis (DCC). However, DAA treatment was associated with decreased risk of liver-related and all-cause mortality.
Review
Gastroenterology & Hepatology
Patrice Cacoub, Cloe Comarmond, Matheus Vieira, Paul Regnier, David Saadoun
Summary: HCV infection can induce various B-cell lymphoproliferative disorders, and treatment strategies usually involve direct-acting antiviral drugs. However, the positive impact of these drugs on B-cell non-Hodgkin lymphoma requires further confirmation through larger studies.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Eiichi Ogawa, Makoto Nakamuta, Norihiro Furusyo, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Kazuhiro Takahashi, Takeaki Satoh, Toshimasa Koyanagi, Nobuyuki Yamashita, Yasunori Ichiki, Naoki Yamashita, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Masaki Kato, Shinji Shimoda, Hideyuki Nomura, Jun Hayashi
Summary: This study assessed the long-term trends and predictors of hepatocellular carcinoma recurrence after hepatitis C virus cure by direct-acting antivirals. Results showed that cirrhosis, number of HCC nodules, and previous palliative treatment were independent predictors of late recurrence.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Gastroenterology & Hepatology
Hui Liu, Xiao-Li Yang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Dong-Xu Wang, Tao Li
Summary: This study evaluated the effect of direct-acting antivirals (DAAs) therapy on the clinical outcomes of hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC). The results showed that DAAs therapy can reduce recurrence and improve overall survival (OS) in HCV-related HCC patients, especially for patients with sustained virologic response (SVR).
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Jolanta Zegarska, Ewa Wiesik-Szewczyk, Ewa Hryniewiecka, Beata Wolska-Kusnierz, Dariusz Soldacki, Magdalena Kacprzak, Agnieszka Sobczynska-Tomaszewska, Kamila Czerska, Pawel Siedlecki, Karina Jahnz-Rozyk, Ewa Bernatowska, Radoslaw Zagozdzon, Leszek Paczek
Summary: TRAPS is a rare systemic autoinflammatory disease that is genetically conditioned and can be diagnosed through clinical symptoms and genetic testing. Early diagnosis followed by appropriate clinical management can prevent irreversible complications.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Natalia Krata, Bartosz Foroncewicz, Radoslaw Zagozdzon, Barbara Moszczuk, Magdalena Zielenkiewicz, Leszek Paczek, Krzysztof Mucha
Summary: IgA nephropathy, membranous nephropathy, and lupus nephritis are important causes of chronic kidney disease, with distinct pathogenesis, clinical courses, and treatment responses. This study found differences in serum concentrations of PRDXs between different types of glomerulonephritis, which were associated with glomerular filtration rate, complement levels, hemoglobin, and body mass index.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
(2022)
Article
Oncology
Marta Klopotowska, Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Agnieszka Kraft, Zofia Pilch, Andriy Zhylko, Malgorzata Firczuk, Iwona Baranowska, Michal Lazniewski, Dariusz Plewczynski, Agnieszka Goral, Karolina Soroczynska, Joanna Domagala, Katsiaryna Marhelava, Aleksander Slusarczyk, Kuba Retecki, Kavita Ramji, Marta Krawczyk, Madison N. Temples, Blanka Sharma, Mieszko Lachota, Herman Netskar, Karl-Johan Malmberg, Radoslaw Zagozdzon, Magdalena Winiarska
Summary: Oxidative stress is a characteristic feature of cancer, and increased hydrogen peroxide concentrations affect immune cell functions. NK cells are more susceptible to hydrogen peroxide and lack peroxiredoxin-1.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Oncology
Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sebastien Walchli, Magdalena Winiarska, Radoslaw Zagozdzon
Summary: This study provides new information on the efficacy of PD-L1-targeted CAR against PD-L1(low) targets. The results show that PD-L1-CAR cells have strong reactivity and cytotoxicity against both PD-L1(high) and PD-L1(low) target cells. Additionally, PD-L1-CAR cells also exhibit potent cytotoxic effects against non-malignant cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Natasza Olszowska-Zaremba, Radoslaw Zagozdzon, Jolanta Gozdowska
Summary: This study evaluated the predictive potential of virtual crossmatch (VXM) results for CDCXM and FLXM results in sensitized patients. The results showed that VXM had better predictability for FLXM results than for CDCXM results.
TRANSPLANT IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Aleksander Roszczyk, Jadwiga Turlo, Radoslaw Zagozdzon, Beata Kaleta
Summary: Shiitake mushroom, also known as Lentinula edodes, is a popular edible fungus that contains valuable polysaccharides with anticancer, antioxidant, antimicrobial, and immunomodulatory properties. The biological activity of these polysaccharides depends on the extraction method.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Oncology
Radoslaw Zagozdzon, Magdalena Winiarska, Malgorzata Firczuk
Review
Oncology
Rafal Staros, Agata Michalak, Kinga Rusinek, Krzysztof Mucha, Zygmunt Pojda, Radoslaw Zagozdzon
Summary: The ability of cancer cells to evade the host's immune response is crucial for developing effective anticancer therapies. Traditional cell culture techniques are inadequate for studying immune evasion due to the complexity of the tumor microenvironment. However, recent advancements in 3D bioprinting offer promising opportunities for modeling immune evasion and response to immunotherapies in oncological research.
Article
Immunology
Natasza Olszowska-Zaremba, Jolanta Gozdowska, Radoslaw Zagozdzon
Summary: This study aimed to evaluate the clinical significance of low pre-transplant DSA in living donor kidney recipients. The study found that the presence of low pre-transplant DSA does not lead to deterioration in graft function and worse graft survival.
TRANSPLANT IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Aleksander Roszczyk, Michal Zych, Katarzyna Zielniok, Natalia Krata, Jadwiga Turlo, Marzenna Klimaszewska, Radoslaw Zagozdzon, Beata Kaleta
Summary: The polysaccharides isolated from Lentinula edodes, particularly the Se-Le-30 fraction, have shown immunomodulatory effects on human T lymphocytes by inhibiting proliferation of CD3-stimulated T cells and enhancing cytokine synthesis. These findings suggest the potential use of Se-Le-30 as a therapeutic compound in immunomodulation research.
Review
Immunology
Marta Sledz, Alicja Wojciechowska, Radoslaw Zagozdzon, Beata Kaleta
Summary: Chimeric antigen receptor-T (CAR-T) cell-based therapy has shown success in treating various hematological malignancies and has potential for non-malignant diseases. However, the traditional approach of CAR-T cell generation is complex, time-consuming, and expensive. In situ production of CAR-T cells using viral or non-viral delivery systems has been shown to address these issues and reduce toxicities associated with CAR-T therapy. This review highlights the current state and future prospects of in situ-produced CAR-T cells.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
(2023)
Correction
Immunology
Marta Sledz, Alicja Wojciechowska, Radoslaw Zagozdzon, Beata Kaleta
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
(2023)
Article
Nutrition & Dietetics
Malgorzata Kalucka, Aleksander Roszczyk, Marzenna Klimaszewska, Beata Kaleta, Ewelina Drelich, Anna Blazewicz, Sandra Gorska-Jakubowska, Eliza Malinowska, Marek Krol, Aleksandra Maria Prus, Katarzyna Trzesniowska, Aleksandra Wolczynska, Przemyslaw Dorozynski, Radoslaw Zagozdzon, Jadwiga Turlo
Summary: In this study, mycelial cultures of Lentinula edodes were used to obtain selenium-containing immunomodulatory preparations. The researchers also aimed to investigate the simultaneous accumulation of selenium and zinc in these mycelia. The effects of the selenium and zinc extracts on T cell activation in human PBMCs were studied, and significant changes were observed in the expression of PD-1 and CD25 antigens on CD8+ T cells. The selenium and zinc content in the preparations modified the immunomodulatory activity of mycelial polysaccharides, but the mechanisms of action of the active ingredients in the extracts were found to be different.
Article
Medicine, General & Internal
Mieszko Lachota, Katarzyna Zielniok, Daniel Palacios, Minoru Kanaya, Leena Peena, Hanna Julie Hoel, Merete Thune Wiiger, Lise Kveberg, Wojciech Hautz, Radoslaw Zagozdzon, Karl-Johan Malmberg
Summary: Research has found that the chemokine receptor repertoire of peripheral blood NK cells changes during NK cell differentiation and is closely associated with the migratory response of different NK cell subsets. Simultaneous stimulation of CXCR1/2 and CX3CR1 receptors can synergistically enhance the migratory response of NK cells. The lack of naturally occurring chemokine-chemokine receptor pairs in human cancers may explain the exclusion of NK cells from the tumor microenvironment.
Article
Oncology
Agnieszka Goral, Marta Sledz, Aneta Manda-Handzlik, Adrianna Cieloch, Alicja Wojciechowska, Mieszko Lachota, Agnieszka Mroczek, Urszula Demkow, Radoslaw Zagozdzon, Katarzyna Matusik, Malgorzata Wachowska, Angelika Muchowicz
Summary: The crosstalk between Treg and neutrophils may play an important role in CLL progression by interfering with the immune response.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
